Durable Mechanical Circulatory Support: JACC Scientific Statement
Recommended Citation
Tedford RJ, Leacche M, Lorts A, Drakos SG, Pagani FD, and Cowger J. Durable Mechanical Circulatory Support: JACC Scientific Statement. J Am Coll Cardiol 2023; 82(14):1464-1481.
Document Type
Article
Publication Date
10-3-2023
Publication Title
Journal of the American College of Cardiology
Abstract
Despite advances in medical therapy for patients with stage C heart failure (HF), survival for patients with advanced HF is <20% at 5 years. Durable left ventricular assist device (dLVAD) support is an important treatment option for patients with advanced HF. Innovations in dLVAD technology have reduced the risk of several adverse events, including pump thrombosis, stroke, and bleeding. Average patient survival is now similar to that of heart transplantation at 2 years, with 5-year dLVAD survival now approaching 60%. Unfortunately, greater adoption of dLVAD therapy has not been realized due to delayed referral of patients to advanced HF centers, insufficient clinician knowledge of contemporary dLVAD outcomes (including gains in quality of life), and deprioritization of patients with dLVAD support waiting for heart transplantation. Despite these challenges, novel devices are on the horizon of clinical investigation, offering smaller size, permitting less invasive surgical implantation, and eliminating the percutaneous lead for power supply.
Medical Subject Headings
Humans; Quality of Life; Heart Failure; Heart Transplantation; Heart-Assist Devices; Stroke; Treatment Outcome
PubMed ID
37758441
Volume
82
Issue
14
First Page
1464
Last Page
1481
